Pralatrexate

CAS: 146464-95-1

Ref. 3D-FP159010

Produktinformation

• Name: Pralatrexate
• Synonyme: <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-, <span class="text-smallcaps">L</span>-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]-, Folotyn, N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-<span class="text-smallcaps">L</span>-glutamic acid, N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid, NSC 754230, L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]-, N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-L-glutamic acid, 10-Propargyl-10-deazaaminopterin, L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-, PDX

Beschreibung

Pralatrexate is a drug that belongs to a group of drugs called DNA-damaging agents. It is used for the treatment of t-cell lymphomas and has been shown to be effective in vitro and in vivo. Pralatrexate is a prodrug that undergoes enzymatic conversion to form a phosphoramide mustard, which induces DNA damage by inhibiting DNA synthesis and repair. Pralatrexate has minimal toxicity and does not cross the blood-brain barrier or cause bone marrow suppression, making it an attractive agent for the treatment of t-cell lymphomas.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 477.47 g/mol
• Formel: C₂₃H₂₃N₇O₅
• Reinheit: Min. 95%
• Farbe/Form: Powder